Savara Overview
Share Price
$2.45
(As of Thursday Closing)
Savara General Information
Description
Savara Inc is a pharmaceutical company. The company develops novel therapies for the treatment of serious or life-threatening rare respiratory diseases. It offers products such as AeroVanc, for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, for the treatment of autoimmune pulmonary alveolar proteinosis and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction. All the business activity of the firm is functioned through the region of United States.
Savara Timeline
Want to dig into this profile?
We’ll help you find what you need
Learn more
Savara Stock Performance
(As of Tuesday closing)
| Stock Price |
Previous Close |
52 wk Range |
Market Cap |
Shares |
Average Volume |
EPS |
| $2.45 |
$2.52 |
$0.69 - $11.39 |
$132M |
52.2M |
324K |
-$1.86 |
Savara Financials Summary
In Thousands,
USD
|
TTM
31-Mar-2020
|
FY 2019
31-Dec-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
| EV |
11,569 |
146,739 |
169,302 |
414,581 |
| Revenue |
0 |
0 |
0 |
0 |
| EBITDA |
(80,327) |
(77,093) |
(68,058) |
(31,907) |
| Net Income |
(81,482) |
(78,173) |
(61,516) |
(29,797) |
| Total Assets |
119,975 |
136,203 |
152,287 |
159,628 |
| Total Debt |
25,042 |
25,552 |
24,571 |
15,337 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Savara Valuation & Funding
| Deal Type |
Date |
Amount |
Valuation/
EBITDA |
Post-Val |
Status |
Debt |
This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.
Request a free trial
Savara Cap Table
| Stock |
# of Shares
Authorized |
Par Value |
Dividend Rate (%) |
Original
Issue Price |
Liquidation |
Liquidation
Pref. Multiple |
Conversion
Price |
% Owned |
This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.
Request a free trial
Savara Competitors (13)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| Lung Therapeutics |
Venture Capital-Backed |
Austin, TX |
0 |
000.00 |
00000000000 |
000.00 |
| 0000000000 0000000 |
Venture Capital-Backed |
Brighton, United Kingdom |
0 |
000.00 |
0000000000 0 |
000.00 |
| 000000000 |
Corporation |
Southampton, United Kingdom |
0 |
000.00 |
000000000 |
000.00 |
| 000000 000000 |
Corporation |
London, United Kingdom |
00 |
000.00 |
000000000 |
000.00 |
| 000000 000000 |
Accelerator/Incubator Backed |
Morristown, NJ |
0 |
00.000 |
0000000000 |
00.000 |
Savara Executive Team (11)
| Name |
Title |
Board Seat |
Contact Info |
| Robert Neville |
Co-Founder, Chairman and Chief Executive Officer |
|
|
| David Lowrance |
Chief Financial Officer, Finance & Chief Accounting Officer, Accounting |
|
|
| Taneli Jouhikainen Ph.D |
Founder & Chief Operating Officer, Operations |
|
|
| John Lord Ph.D |
Senior Vice President & Head of Research and Development |
|
|
| Badrul Chowdhury Ph.D |
Chief Medical Officer |
|
|
6 Former Executives
Savara Board Members (8)
To view Savara‘s full board member team, request access >>
| Name |
Representing |
Role |
Since |
| David Ramsay |
Self |
Board Member |
000 0000
|
| Joseph McCracken |
Self |
Board Member |
000 0000
|
| Matthew Pauls JD |
Self |
Board Member |
000 0000
|
| Nevan Elam JD |
Self |
Board Member |
000 0000
|
| Richard Hawkins |
Self |
Board Member |
000 0000
|
3 Former Board Members
Savara Investors
| Investor Name |
Investor Type |
Holding |
Investor Since |
Participating Rounds |
Contact Info |
This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.
Request a free trial
Savara
Investments
&
Acquisitions (3)
To view Savara‘s complete investment and acquisition history, request access >>
| Company Name |
Deal Date |
Deal Type |
Deal Size |
Industry |
Lead Partner |
| 0000000 000000 (00 |
25-Jul-2018 |
000000000 00000 00 |
|
Pharmaceuticals |
000000 0000000 |
| 0000 000000000000 |
27-Apr-2017 |
000000000000000000 |
00000 |
Pharmaceuticals |
000000 0000000 |
| Serendex Pharmaceuticals |
21-Jun-2016 |
Corporate Asset Purchase |
|
Drug Discovery |
000000 0000000 |